# Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

> **NCT02685293** · PHASE3 · TERMINATED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** GFF MDI (PT003)
- **DRUG:** Placebo MDI

## Key facts

- **NCT ID:** NCT02685293
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-09
- **Primary completion:** 2018-06-06
- **Final completion:** 2018-06-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02685293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02685293, "Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02685293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*